Close

Janssen Announces Phase 3b PIONEER AF-PCI Study Data Accepted for Late-Breaking Presentation at AHA Conference

November 7, 2016 8:12 AM EST Send to a Friend
Janssen Pharmaceuticals, Inc. (Janssen) announced that results from the Phase 3b PIONEER AF-PCI study with XARELTO (rivaroxaban) and new INVOKANA ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login